We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
17 October 2018
On 11 July 2018 Health Canada released the Therapeutic Products Directorate Statistical Report 2017/2018, which provided an overview of its administration of the Patented Medicines (Notice of Compliance) (PMNOC) Regulations and data protection regime.
The report includes information regarding trends in listing on the Patent Register and the Register of Innovative Drugs, as well as related court activity. The report shows a downward trend of new patents being added to the Patent Register (606 in 2017 to 2018 compared with 769 in 2016 to 2017), along with an increase in the number of rejections (120 in 2017 to 2018 compared with 74 in 2016 to 2017).
In addition, there was an increase in the number of new human drugs added to the Register of Innovative Drugs (37 in 2017 to 2018 compared with 31 in 2016 to 2017).
The number of prohibition applications commenced as a result of notices of allegations served prior to the amendments to the PMNOC Regulations coming into force on 21 September 2017 increased from 32 in 2016 to 2017 to 41 in 2017 to 2018. Further, 12 actions were reported to have been commenced following the implementation of the amended regulations (as of 31 March 2018).
For further information on this topic please contact Andrew Mandlsohn at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.